SavedAdd your journal

Journals / Uludağ Üniversitesi Tıp Fakültesi Dergisi / 2026 / Cilt: 52

The Role of Survivin in Systemic Lupus Erythematosus: Its Relationship with Diagnosis and Disease Activity

Sistemik Lupus Eritematozus’ta Survivinin Rolü: Tanı ve Hastalık Aktivitesi ile İlişkisi

Zeynep Yağbasan(Bursa Uludağ University Faculty of Medicine, Division of Rheumatology, Bursa, Türkiye.)0000-0003-1373-6140
Servet Yolbaş(İnönü University Faculty of Medicine, Division of Rheumatology, Malatya, Türkiye.)0000-0001-8516-9769
Cihat Uçar(Malatya Turgut Özal University of Medicine, Department of Physiology, Malatya, Türkiye.)0000-0003-3278-7779
Sedat Yıldız(İnönü University Faculty of Medicine, Department of Physiology, Malatya, Türkiye.)0000-0002-7872-790X
Pages
—
Publication Date
2026-03-17
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This study shows that survivin holds significant potential in the diagnosis, disease monitoring, and pathophysiological understanding of SLE, providing foundational data for future research.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Systemic Lupus Erythematosus (SLE) is a chronic connective tissue disease of unclear etiopathogenesis characterized by affecting multiple organs and systems.
📊
Key Findings & Data:In the pathogenesis of SLE, increased apoptosis is thought to play a significant role.
💡
Conclusion & Impact:This study shows that survivin holds significant potential in the diagnosis, disease monitoring, and pathophysiological understanding of SLE, providing foundational data for future research.
🔬Design:Araştırma Makalesi
📍Scope:2019 Verileri
⚙️Variables:SURVİVİN · APOPİTOZİS · SİSTEMİK LUPUS ERİTEMATOZUS

Abstract

Systemic Lupus Erythematosus (SLE) is a chronic connective tissue disease of unclear etiopathogenesis characterized by affecting multiple organs and systems. Survivin, an apoptosis inhibitor protein (IAP) family member is involved in apoptosis, cell division, development and differentiation. In the pathogenesis of SLE, increased apoptosis is thought to play a significant role. Therefore, this study aims to investigate the relationship between survivin levels and disease activity, etiopathogenesis, and biomarkers related to apoptosis and inflammation in patients with SLE. The study included 36 patients with SLE, 17 patients with Sjögren’s syndrome (SjS) and 29 healthy controls who applied to the department, met the eligibility criteria and were non-consecutively enrolled between September 2019 and March 2020. Blood and urine samples were collected and analyzed using enzyme-linked immunoassay (ELISA) method. SLE activity was assessed using SLE Disease Activity Index (SLEDAI) and Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) criteria. SjS activity was assessed using EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI). Plasma survivin levels were significantly lower in SLE patients compared to healthy controls (p<0.001). A strong positive correlation was found between plasma survivin levels and apoptotic and inflammatory markers in SLE patients (p<0.001). No correlation was found between urinary survivin levels, plasma survivin levels and inflammatory, apoptotic markers in SLE (p>0.05). No significant correlation was found between SLEDAI scores and either plasma or urinary survivin levels (p > 0.05). This study shows that survivin holds significant potential in the diagnosis, disease monitoring, and pathophysiological understanding of SLE, providing foundational data for future research.

Özet

Sistemik Lupus Eritematozus (SLE), etiyopatogenezi tam olarak aydınlatılamamış, birden fazla organ ve sistemi etkileyen kronik bir bağ dokusu hastalığıdır. Apoptoz inhibitörü protein (IAP) ailesinin bir üyesi olan survivin; apoptoz, hücre bölünmesi, gelişim ve farklılaşma süreçlerinde rol almaktadır. SLE patogenezinde artmış apoptozun önemli bir rol oynadığı düşünülmektedir. Bu nedenle bu çalışma, SLE hastalarında survivin düzeyleri ile hastalık aktivitesi, etiyopatogenez ve apoptoz ile inflamasyonla ilişkili biyobelirteçler arasındaki ilişkiyi araştırmayı amaçlamaktadır. Çalışmaya, Eylül 2019 ile Mart 2020 tarihleri arasında başvuran, uygunluk kriterlerini karşılayan ve ardışık olmayan şekilde çalışmaya dahil edilen 36 SLE hastası, 17 Sjögren sendromu (SjS) hastası ve 29 sağlıklı kontrol dahil edilmiştir. Kan ve idrar örnekleri toplanmış ve enzim bağlantılı immünosorbent analiz (ELISA) yöntemi kullanılarak analiz edilmiştir. SLE hastalık aktivitesi, SLE Hastalık Aktivite İndeksi (SLEDAI) ve Sistemik Lupus Uluslararası İş Birliği Klinikleri (SLICC)/Amerikan Romatoloji Koleji (ACR) kriterleri kullanılarak değerlendirilmiştir. SjS aktivitesi ise EULAR Sjögren Sendromu Hastalık Aktivite İndeksi (ESSDAI) ile değerlendirilmiştir. Plazma survivin düzeyleri, SLE hastalarında sağlıklı kontrollere kıyasla anlamlı derecede daha düşük bulunmuştur (p<0,001). SLE hastalarında plazma survivin düzeyleri ile apoptotik ve inflamatuvar belirteçler arasında güçlü bir pozitif korelasyon saptanmıştır (p<0,001). SLE hastalarında idrar survivin düzeyleri ile plazma survivin düzeyleri ve inflamatuvar ya da apoptotik belirteçler arasında herhangi bir korelasyon bulunmamıştır (p>0,05). SLEDAI skorları ile plazma veya idrar survivin düzeyleri arasında da anlamlı bir ilişki saptanmamıştır (p>0,05). Bu çalışma, survivinin SLE’nin tanısı, hastalık izlemi ve patofizyolojik mekanizmalarının anlaşılmasında önemli bir potansiyele sahip olduğunu göstermekte ve gelecekte yapılacak araştırmalar için temel veriler sunmaktadır.

🔖

Cite This Article

Yağbasan, Z., Yolbaş, S., Uçar, C., Yıldız, S., *, Z. Y. (2026). The Role of Survivin in Systemic Lupus Erythematosus: Its Relationship with Diagnosis and Disease Activity. Uludağ Üniversitesi Tıp Fakültesi Dergisi, Cilt: 52. https://doi.org/10.32708/uutfd.1818835

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Colglazier CL, Sutej PG, Morris C. Laboratory testing in the rheumatic diseases: A practical review. South Med J. 2005;98:185–91.
  2. Yargucu Zihni F, Keser G. Sistemik Lupus Eritematozus Epidemiyolojisi. Türkiye Klin. 2018;1–5.
  3. Fava A, Petri M. Systemic lupus erythematosus: Diagnosis and clinical management. J Autoimmun. 2019;1–13.
  4. Coşkun G, Özgür H. Apoptoz ve Nekrozun Moleküler Mekanizması. Arşiv Kaynak Tarama Derg. 2014;20:145–58.
  5. Pan L, Lu MP, Wang JH, Xu M, Yang SR. Immunological pathogenesis and treatment of systemic lupus erythematosus. World J Pediatr. 2020;16:19–30.
  6. Pan Q, Chen J, Guo L, Lu X, Liao S, Zhao C, et al. Mechanistic insights into environmental and genetic risk factors for systemic lupus erythematosus. Am J Transl Res. 2019;11:1241–54.
  7. Bertsias GK, Salmon JE, Boumpas DT. Therapeutic opportunities in systemic lupus erythematosus: State of the art and prospects for the new decade. Ann Rheum Dis. 2010 Sep;69:1603–11.
  8. Ebrahimiyan H, Aslani S, Rezaei N, Jamshidi A, Mahmoudi M. Survivin and autoimmunity; the ins and outs. Immunol Lett. 2018;193:14–24.
  9. Eröz R, Bircan D, Yüce H, Özmerdivenli R. Survivin Hakkında Bilinenler: Survivin ile İlgili Türkiye ’ de Yapılmış Olan Çalışmalar. 2015;5:39–58.
  10. Vitali C, Bootsma H, Bowman SJ, Dorner T, Gottenberg JE, Mariette X, et al. Classification criteria for Sjögren’s syndrome: We actually need to definitively resolve the long debate on the issue [Internet]. Vol. 72, Annals of the Rheumatic Diseases. BMJ Publishing Group Ltd; 2013 [cited 2020 Jul 18]. p. 476–8. Available from: https://ard.bmj.com/content/72/4/476
  11. Yin Z hua, Ye Z zhong, Luo X xia. The Abnormal Expression of Survivin Gene in SLE Patients. Prog Mod Biomed. 2007;7:1033–8.
  12. Ebrahimian S, Rashtchizadeh N, Ghorbanihaghjo A, Mahdavi AM, Hajialilo M, Khabbazi A. Association between serum levels of survivin and systemic lupus erythematosus. Int J Clin Pract [Internet]. 2021 Mar 1 [cited 2021 Aug 22];75(3):e13706. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/ijcp.13706
  13. Lisboa RV, de Oliveira FR, Quaresma TO, de Almeida RM, Ribeiro Oliveira RD, Junior PL. The Behaviour of Serum Survivin in Patients With Lupus Nephritis. Biomark Insights [Internet]. 2022 [cited 2025 Mar 24];17:11772719221131470. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9597205/
  14. Koike Y, Muroi E, Yoshizaki A, Ogawa F, Yanaba K, Takenaka M, et al. Autoantibody against survivin in patients with systemic sclerosis. J Rheumatol [Internet]. 2010 Sep 1 [cited 2020 Aug 28];37(9):1864–70. Available from: www.jrheum.org
  15. Ramos-Casals M, Font J. Primary Sjögren’s syndrome: Current and emergent aetiopathogenic concepts. Rheumatology. 2005;44:1354–67.